Patent acquisition puts VolitionRX in prime position.....
NAMUR, Belgium, Feb. 24, 2015 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, today announced that it has just acquired the unencumbered assignment of the patent family WO 2005/019826 originally filed by Chroma Therapeutics Limited, a UK-based biotechnology company. VolitionRx's rights to this patent were previously held through a world-wide exclusive licensing agreement. Following this assignment, VolitionRx directly owns all core Nucleosomics® patents with no royalties or other encumbrances.
The WO 2005/019826 patent family relates to developments, made by scientists working at Chroma Therapeutics Limited, in the detection of chemically modified chromosome fragments, called nucleosomes, from cancer cells circulating in the blood of cancer patients. The scientists were able to show that cancer could be detected by measuring nucleosomes containing chemically modified histone proteins in a simple blood test.
Cameron Reynolds, Chief Executive Officer of VolitionRx, remarked, "The acquisition of this patent further strengthens VolitionRx's market and IP position in this exciting platform technology, maximizing the value of our Nucleosomics® platform for the company. Having all the core Nucleosomics IP completely royalty free is a very positive outcome for the retention of the value we aim to create for our shareholders."
Dr. Jake Micallef, Chief Scientific Officer of VolitionRx, commented, "We congratulate Chroma Therapeutics Limited for their pioneering work. Scientists working at VolitionRx have developed further innovative Nucleosomics® methods and tests for a wide variety of chromatin fragment structures to continuously expand our patent portfolio, which currently stands at 10 families of granted patents and pending applications."
Market Data 
Markets 
AI
